Drug Trial Radar · NCT01307579
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
Last checked: Nov 20, 2026Latest source record: Mar 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
517
Actual
Start
Apr 4, 2011
Primary completion
Jun 30, 2018
Study completion Jun 30, 2020
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Mar 3, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- Who can join
- All sexes, from 3 months, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial compares the effectiveness of caspofungin to fluconazole in preventing invasive fungal infections in patients receiving chemotherapy for acute myeloid leukemia (AML). Antifungal prophylaxis is considered standard of care in children and adults with prolonged neutropenia after chemotherapy for AML however the ideal antifungal agent for prophylaxis in children is not known. Caspofungin has activity against yeast and some molds while fluconazole coverage is limited to just yeasts. Adult randomized trials suggest that agents with activity against yeasts and molds are more effective than those with just activity against yeasts. There are limited data to answer this comparative question in children. This study will establish much needed pediatric data to guide clinical decision making on optimal antifungal prophylaxis.
Conditions
- Acute Myeloid Leukemia
- Adult Acute Monoblastic Leukemia
- Adult Acute Monocytic Leukemia
- Adult Acute Myeloid Leukemia in Remission
- Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- Adult Acute Myeloid Leukemia With Maturation
- Adult Acute Myeloid Leukemia With Minimal Differentiation
- Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
- Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
- Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A
- Adult Acute Myeloid Leukemia Without Maturation
- Adult Acute Myelomonocytic Leukemia
- Alkylating Agent-Related Acute Myeloid Leukemia
- Childhood Acute Monoblastic Leukemia
- Childhood Acute Monocytic Leukemia
- Childhood Acute Myeloid Leukemia in Remission
- Childhood Acute Myeloid Leukemia With Maturation
- Childhood Acute Myeloid Leukemia With Minimal Differentiation
- Childhood Acute Myeloid Leukemia Without Maturation
- Childhood Acute Myelomonocytic Leukemia
- Fungal Infection
- Myeloid Neoplasm
- Neutropenia
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Childhood Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia
- Untreated Adult Acute Myeloid Leukemia
- Untreated Childhood Myeloid Neoplasm
Interventions
Caspofungin AcetateDrug
Given IV
FluconazoleDrug
Given IV or PO
Laboratory Biomarker AnalysisOther
Correlative studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Proven or Probable Invasive Fungal Infections (IFI)Time frame: Up to 5 months since enrollment
Locations
179 sites in 3 countries. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Phoenix Childrens Hospital
Phoenix, Arizona
Arkansas Children's Hospital
Little Rock, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Kaiser Permanente Downey Medical Center
Downey, California
Loma Linda University Medical Center
Loma Linda, California
Miller Children's and Women's Hospital Long Beach
Long Beach, California
Children's Hospital Los Angeles
Los Angeles, California
Cedars Sinai Medical Center
Los Angeles, California
Valley Children's Hospital
Madera, California
Kaiser Permanente-Oakland
Oakland, California
Children's Hospital of Orange County
Orange, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Rady Children's Hospital - San Diego
San Diego, California
UCSF Medical Center-Parnassus
San Francisco, California
UCSF Medical Center-Mission Bay
San Francisco, California
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, California
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
Denver, Colorado
Connecticut Children's Medical Center
Hartford, Connecticut
Yale University
New Haven, Connecticut
Alfred I duPont Hospital for Children
Wilmington, Delaware
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Children's National Medical Center
Washington D.C., District of Columbia
Broward Health Medical Center
Fort Lauderdale, Florida
Lee Memorial Health System
Fort Myers, Florida
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida
University of Florida Health Science Center - Gainesville
Gainesville, Florida
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida
Nemours Children's Clinic-Jacksonville
Jacksonville, Florida
Florida Hospital Orlando
Orlando, Florida
Nemours Children's Clinic - Orlando
Orlando, Florida
UF Cancer Center at Orlando Health
Orlando, Florida
Nemours Children's Hospital
Orlando, Florida
Nemours Children's Clinic - Pensacola
Pensacola, Florida
Johns Hopkins All Children's Hospital
St. Petersburg, Florida
Tampa General Hospital
Tampa, Florida
Saint Joseph's Hospital/Children's Hospital-Tampa
Tampa, Florida
Saint Mary's Hospital
West Palm Beach, Florida
Children's Healthcare of Atlanta - Egleston
Atlanta, Georgia
Showing 40 of 179 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.